secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emergent BioSolutions Inc. (EBS)
CIK:        0001367644
Form:       8-K
Filed at:   2023-04-17T23:59:59+00:00
Accession:  0001367644-23-000082
Event type: debt
Sentiment:  neutral
Materiality: 0.85
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emergent BioSolutions extends limited waiver of credit covenant compliance through May 17, 2023
--------------------------------------------------------------------------------

- Entered into Waiver Amendment to Credit Agreement Amendment dated February 14, 2023, with lenders led by Wells Fargo.
- Extended Limited Waiver covers defaults from financial covenant violations for fiscal quarters ending Dec 31, 2022 and Mar 31, 2023.
- Waiver also addresses going concern qualification in audited financial statements for fiscal year ending December 31, 2022.
- Company is working with lenders to replace current credit facility and extend the October 2023 maturity.
- Company previously announced sale of travel health business to Bavarian Nordic for up to $380 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000082/0001367644-23-000082-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1367644/000136764423000082/ebs-20230417.htm
  HTML page:      https://secwatch.observer/filing/0001367644-23-000082

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer